Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-associated virus (AAV) vector-based gene therapies. Mild to severe adverse events observed in clinical development have been implicated with host immune responses against AAV gene therapies, resulting in comprehensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Tong-yuan, Braun, Manuela, Lembke, Wibke, McBlane, Fraser, Kamerud, John, DeWall, Stephen, Tarcsa, Edit, Fang, Xiaodong, Hofer, Lena, Kavita, Uma, Upreti, Vijay V., Gupta, Swati, Loo, LiNa, Johnson, Alison J., Chandode, Rakesh Kantilal, Stubenrauch, Kay-Gunnar, Vinzing, Maya, Xia, Cindy Q., Jawa, Vibha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418752/
https://www.ncbi.nlm.nih.gov/pubmed/36092368
http://dx.doi.org/10.1016/j.omtm.2022.07.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418752/
https://www.ncbi.nlm.nih.gov/pubmed/36092368
http://dx.doi.org/10.1016/j.omtm.2022.07.018

Ejemplares similares